133 B Cell Depletion Therapy Resulting in Sustained Remission of Severe Autoimmune Complications Following Alemtuzumab Treatment of Multiple Sclerosis

Journal of Neurology, Neurosurgery and Psychiatry - United Kingdom
doi 10.1136/jnnp-2019-anzan.118
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

A Case of Autoimmune Myositis After Treatment With Alemtuzumab for Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2018English

Immune Competence After Alemtuzumab Treatment of Multiple Sclerosis

Neurology
Neurology
2013English

Alemtuzumab Following Natalizumab in Highly Active Paediatric-Onset Multiple Sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical
2019English

Differential Reconstitution of T Cell Subsets Following Immunodepleting Treatment With Alemtuzumab (Anti-Cd52 Monoclonal Antibody) in Patients With Relapsing-Remitting Multiple Sclerosis

Journal of Immunology
AllergyImmunology
2013English

Adverse Events With Fatal Outcome Associated With Alemtuzumab Treatment in Multiple Sclerosis

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2019English

Comparative Efficacy of Alemtuzumab And established Treatment in the Management Of multiple Sclerosis

Neuropsychiatric Disease and Treatment
2015English

Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
2017English

AB0458 B Cells Depletion for the Treatment of Systemic Autoimmune Diseases

2017English

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy